Men | Women | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
MetSd | MetSd | |||||||||
Yes | No | OR (95% CI)a | OR (95% CI)b | OR (95% CI)c | Yes | No | OR (95% CI)a | OR (95% CI)b | OR (95% CI)c | |
Absolute MVPAe recommendation | ||||||||||
Below | 158 | 178 | 1.68 (1.15–2.46) | 1.69 (1.15–2.50) | 1.36 (0.90–2.06) | 135 | 241 | 1.35 (0.93–1.97) | 1.32 (0.90–1.94) | 0.77 (0.5–1.17) |
Meeting | 60 | 113 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 56 | 135 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Absolute MPA recommendation | ||||||||||
Below | 160 | 206 | 1.14 (0.77–1.69) | 1.20 (0.80–1.79) | 1.09 (0.71–1.65) | 135 | 245 | 1.29 (0.88–1.88) | 1.26 (0.86–1.85) | 0.75 (0.49–1.15) |
Meeting | 58 | 85 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 56 | 131 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Absolute VPAf recommendation | ||||||||||
Below | 216 | 275 | 6.43 (1.46–28.35) | 6.16 (1.37–27.57) | 2.88 (0.61–13.68) | 191 | 376 | - | - | - |
Meeting | 2 | 16 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 0 | 0 | - | - | - |